Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma.

ABSTRACT: Topical ophthalmic formulations of analogues of the endogenous arachidonic acid cyclooxygenase metabolite, PGF_2α , are the standard of care treatment for the blinding disease glaucoma. These are the most potent and efficacious medical therapies for lowering intraocular pressure (IOP), the most important risk factor identified for disease progression. They have few side effects and offer the convenience of once-a-day dosing. It was initially believed that endogenous PGs raised IOP and caused substantial ocular surface adverse effects. However, carefully designed experiments demonstrated that esterification of the carboxylic acid afforded potent and efficacious topical ocular hypotensive activity. The final hurdle to be overcome was improvement of the side effect profile. A hypoth

SUBMITTER: Klimko PG 

PROVIDER: S-EPMC6451111 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature